STK26

Across TCGA pan-cancer cohorts, STK26 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STK26 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher STK26 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK26 expression acts as an unfavorable survival marker.

LAML, SCLC, and LGG are the cancer types where STK26 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.589	0.836	.020	4	view →
STAD	OS	Median	All	0.257	0.688	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STK26–LAML (DFS)

Open the LAML breakdown →